drugset

drugset / Trial / NCT06224790

Perfenidone in Type 2 Diabetic Patients With Diabetic Neuropathy

NCT06224790 ↗

Phase 4 Completed 60 enrolled Sidrah Lodhi

RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to determine the effectiveness \& safety of pirfenidone in type 2 diabetic patients with diabetic nephropathy

Timeline

Start: 2024-03-10
Primary completion: 2025-03-07
Completion: 2025-03-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pirfenidone	Small molecule	1200 mg	—

Indications